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Abstract
Background: Mesenchymal stem/progenitor cells (MSC) have shown beneficial effects in many models of disease
in part by modulating excessive inflammatory and immune responses. Frequently the beneficial effects of MSC
persist long after their disappearance from host tissues, suggesting that MSC interact with intermediate cells in the
host that relay or amplify their effects. The cells have usually been injected intravenously, but beneficial effects have
also been reported with intraperitoneal (IP) injection of MSC. However the fate of IP injection of MSC has not been
examined.
Methods: The fate of the human MSC injected IP into immune-competent mice was studied. In vivo imaging
was used to track green fluorescent protein-labeled MSC in the peritoneal cavity. In addition, their retention in
peritoneal tissues was measured by real-time polymerase chain reaction for human GAPDH mRNA. To describe
the effects of human MSC on the immune system of the peritoneum, the peritoneal lavage, omentum, lymph
nodes and mesenteric tissues were collected. Flow cytometry was used to evaluate the immune cell populations,
while cytokine/chemokine production was measured by real-time polymerase chain reaction and enzyme-linked
immunosorbent assay. Challenge with lipopolysaccharide at 3 days after the administration of MSC was used to
evaluate the preconditioning of the immune system.
Results: Within 20 min, single MSC were no longer detected in peritoneal lavage fluid. Instead they were recovered as
aggregates of varying size that contained mouse macrophages and a few B220+ lymphocytes. After 1 day, most of the
aggregates containing live MSC were attached to sites throughout the peritoneal cavity including the omentum and
mesentery. Less than 0.05 % of the live injected cells were detected in the spleen and jejunal lymph nodes. In all
locations, MSC colocalized with mouse macrophages and B220+ lymphocytes. Attachment to the omentum and
mesentery was accompanied by the recruitment of immune cells and changes in the production of a series of mouse
cytokines. A similar increase in mouse cytokines in the peritoneum was seen after IP injections of human fibroblasts.
Conclusions: IP injected human MSC rapidly formed aggregates with mouse macrophages and B220+ lymphocytes
and attached to the walls of the peritoneal cavity. The formation of the aggregates probably limits access of the cells
to the systemic circulation.
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Background
Human mesenchymal stem/progenitor cells (MSC) from
bone marrow, adipose tissues, placenta, umbilical cord
and other tissues are currently being administered to
large numbers of patients. Over 100 clinical trials with
MSC have been registered [1], and several have reached
phase II or III stage of development [2]. In essentially all
the clinical trials, and in most experiments in animal
models, the cells were administered by intravenous (IV)
injection. At the same time, there has also been interest
in administration by injection into the peritoneum (in-
traperitoneal; IP) [3–5]. For example, it has been previ-
ously shown that MSC reach the lungs after IP injection
[6]. One advantage of IP injection is that, because of
slower rate of their migration from the peritoneal cavity,
IP injection could potentially avoid rapid embolization
of the lung vasculature that can be lethal [7]. Also, IP in-
jection allows for the administration of larger numbers
of cells. In addition, in direct comparisons with IV ad-
ministrations, IP injected MSC were shown to have
comparable or even more profound effects in experi-
mental autoimmune encephalitis [8], twitcher mice with
globoid cell leukodystrophy [9], mice with cisplatin-in-
duced renal injury [10], mice with experimental intes-
tinal colitis [11], mice with sterile inflammation of
the cornea [12], and mice with zymosan-induced peri-
tonitis [13]. The beneficial effects of MSC in these
and other disease models have been linked to the
ability of the cells to modify both the innate and ac-
quired immune systems [14, 15].
The peritoneal cavity provides an unusual setting for
immune interactions because it is primed to respond
rapidly to bacteria that may be released by intestinal
spillage [16], allergens such as worms that enter the
gastrointestinal tract, or tumor metastases [17]. The rap-
idity of the response is obviously critical. It is mediated
by at least two special classes of cells. One special class
is the B lymphocytes, particularly B-1b lymphocytes,
found in the peritoneal cavity and other sites such as the
omentum that contain an unusual repertoire of recep-
tors that allow them to mount an immediate antibody
response to bacteria without being part of the adaptive
immune system [18]. The second special class is small
cells that are found in the mesentery and some other lo-
cations in the body and that are triggered by worms and
other allergens to mount a rapid T-helper (Th)2 re-
sponse. The cells are lineage-negative and referred to as
nuocytes among several other terms [19–23]. The cells
generate an innate Th2 response characterized by se-
cretion of interleukin (IL)-4 that facilitates production
of immunoglobulin (Ig)G1 and IgE, and by secretion
of IL-13 that contributes to epithelial hypertrophy
and recruitment of eosinophils, characteristics of al-
lergic responses [19, 22].
The peritoneal cavity is also an unusual setting for
entry into the immune system because it participates in
dynamic exchange of the fluids and cells between the
cavity and both the lymphatic system and the general
circulation. The exchange occurs through three or four
portals that breach the tight layer of basement mem-
brane and mesothelial cells that forms the peritoneal
membrane and that covers all the organs and the walls
of the abdomen: (a) “milky spots” that are opaque, highly
vascularized clusters of cells on the surface of the omen-
tum, the fatty organ that straddles the spleen, stomach
and other organs of the upper abdomen in mice but
covers a much more extensive area in humans; (b) the
draining lymphatic system contained in the stalk of
mesenteric arteries and veins that supplies the gastro-
intestinal tract and in the walls of the peritoneal cavity;
(c) punctate regions called lymphatic stomata on the
underside of the diaphragm; and (d) the newly discov-
ered small cells in the mesentery and other tissues that
mount a rapid Th2 response [19–23]. The milky spots of
the omentum [23, 24] contain clusters of macrophages
and B1 lymphocytes that are similar to the free-floating
macrophages and B1 lymphocytes of the peritoneal cav-
ity. The milky spots readily exchange particulate matter
and cells between the peritoneal cavity and the general
circulation. They may [25] or may not [24] contain resi-
dent dendritic cells that can activate lymphocytes, but
they can recruit T cells activated at other sites. The
draining lymphatics of the mesenteric stalk and periton-
eal wall absorb particles from the gastrointestinal tract,
and both particles and cells from the peritoneal cavity.
The lymphatic stomata on the underside of the dia-
phragm consist of a thin layer of cuboidal cells that
overlay large lacunae of lymphatic vessels [26, 27]. The
lacunae drain primarily into mediastinal lymph nodes
and then to the thoracic duct and eventually the left
subclavian vein.
In exploring the fate of MSC injected into the periton-
eal cavity, several groups of investigators observed en-
graftment of the cells not only into the peritoneum but
also into multiple distal organs [28, 29]. However, the
route the cells traveled was not defined. In initial efforts
to follow the fate of human MSC injected into the peri-
toneum, we recently reported [30] that some of the
MSC aggregated and compacted into spheres similar to
the spheres formed after the cells were cultured in hang-
ing drops. Here we report that, after IP administration
of MSC into immunocompetent mice, the cells rapidly
formed aggregates with macrophages and a few B220+
cells. The aggregates were initially recovered in the peri-
toneal lavage fluid but then they slowly attached to milky
spots in the omentum and to regions of the mesentery.
Apparently, because of the large size of the aggregates,
few of the MSC appeared in mesenteric lymphatic
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nodes, a route previously shown to be favored by IP
injected splenocytes [31]. The MSC disappeared in less
than a week but prompted recruitment of cells to the
omentum and peritoneal cavity that secreted both pro-
and anti-immune mouse cytokines. Similar increases in
mouse cytokines in the peritoneum were seen after IP
administration of human fibroblasts.
Methods
Human mesenchymal stem/stromal cell culture
Human MSCs were obtained from normal, healthy
donors with informed consent under Scott & White
and Texas A&M Institutional Review Boards approved
procedures. Passage 1 wild-type MSC and passage 4
green fluorescent protein-expressing MSC (GFP-MSC)
were obtained as frozen vials from the Center for the
Preparation and Distribution of Adult Stem Cells [32].
Human MSC (donors 7075, 7068, and 7032) were isolated
from bone marrow aspirates and cultured as previously
described [33]. Human GFP-MSCs were generated from
passage 0 wild-type human MSCs using lentiviral vector
containing humanized recombinant form of green fluores-
cent protein under the control of chicken beta-actin pro-
moter and cytomegalovirus enhancer WPT-CAG-hrGFP
(Stratagene) pseudotyped with VSVG envelope in the
presence of polybrene (Sigma). The resultant population
was purified using fluorescent activated cell-sorting
(FACSVantage; Becton Dickinson) and expanded for three
more passages. The cells met the standard criteria for
MSC, including profile of surface epitopes, CFU values
and trilinage differentiation. In vitro growth, differenti-
ation, clonogenicity and epitope markers of MSC prepara-
tions are summarized in Additional file 1 (Table S1)
according to Reger and Prockop [34]. For the experiments
described here, a frozen vial of about 1 million passage 1
MSC was plated in complete culture medium (CCM)
consisting of α-minimum essential medium (αMEM;
Gibco, Grand Island, NY), 17 % fetal bovine serum (FBS;
Atlanta Biologicals, Lawrenceville, GA), 100 units/ml
penicillin (Gibco), 100 mg/ml streptomycin (Gibco), and
2 mM L-glutamine (Gibco) on a 152 cm2 culture dish
(Corning, Acton, MA) for 24 h. Cells were washed with
phosphate-buffered saline (PBS) and the adherent viable
cells were harvested using 0.25 % trypsin and 1 mM ethyl-
enediaminetetraacetic acid (EDTA; Gibco) for 3–4 min at
37 °C, reseeded at 100–200 cells/cm2 in CCM and incu-
bated for 6–7 days (with medium change every 2–3 days)
before freezing in αMEM containing 30 % FBS and 5 %
dimethylsulfoxide (Sigma, St. Louis, MO). For the in vivo
experiments, the cells were recovered as passage 2 (MSC)
and passage 5 (GFP-MSC), cultured for 24 h, and re-
plated at 100–200 cells/cm2. The cells were cultured for
6–7 days and harvested with trypsin-EDTA, washed once
in Hanks Balanced Salt Solution (HBSS; Lonza, Basel,
Switzerland) containing 0.1 % FBS and then again washed
with serum-free HBSS. The cells were finally reconstituted
at 1 × 104 cells/μl to a total amount of 0.3–3 × 106 cells in
serum-free HBSS and kept on ice for the injections.
Human adult dermal fibroblast culture
Human adult dermal fibroblasts (hDFs) were obtained
from American Type Culture Collection (ATCC). Frozen
vials of the cells were thawed and plated on adherent T-
175 flasks (Corning) in CCM for 24 h. After medium
change, the cells were expanded until approximately 70–
90 % confluent. Cells were harvested with trypsin/EDTA
for 5 min at 37 °C and re-plated at 1000–3000 cells/cm2
for expansion. Medium was changed every 2–4 days and
cells were harvested at 70–90 % confluence for assays.
Single GFP cell measurements in peritoneal cavity
All animal procedures were approved by the Animal
Care and Use Committee of Texas A&M University
Health Science Center and in accordance with guidelines
set forth by the National Institutes of Health.
Male 6-week-old BALB/c mice (Jackson Laboratories,
West Grove, PA) were injected IP with 3 × 106 GFP-
MSC suspended in 300 μl HBSS. At 1 min, 20 min, 4 h
and 72 h after the administration of MSC, mice were eu-
thanized by cervical dislocation under deep anesthesia
and peritoneal lavage was collected by injecting 5 ml of
PBS into the peritoneal cavity followed by harvesting the
lavage with a pipette. Ten microliters of the lavage were
then placed directly in Neubauer hemocytometer in
duplicate, and fluorescent and brightfield images were
taken using inverted Nikon Eclipse Ti-S microscope
(Nikon). The “Analyze Particles” plugin for ImageJ soft-
ware was used to count total and GFP-positive cells.
Real-time PCR for assay of human cell number
To estimate the total number of human cells in the omen-
tum, jejunal lymph nodes, mesentery, spleen and peritoneal
lavage, human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) expression was measured [7, 12]. Standard
curves were prepared by combining known amounts of
MSC with tissues and peritoneal resident cells from
naïve BALB/c mice. Total RNA was isolated using
RNeasy Lipid Tissue Mini Kit (Qiagen) with DNA di-
gestion step using DNAse (Qiagen). Isolated RNA was
quantified using Nanodrop specrophotometer (Thermo
Fisher Scientific) and 0.3–2 μg was converted to cDNA
with High-Capacity cDNA RT Kit (Applied Biosystems,
Foster City, CA). Real-time polymerase chain reaction
(PCR) for eukaryotic 18S ribosomal RNA and human
GAPDH was performed using Taqman Gene Expression
Assays (Applied Biosystems) and Taqman Fast Master
Mix (Applied Biosystems) in triplicate using 20 ng cDNA
in 20 μl reaction. Real-time PCR reaction was performed
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with CFX96 Real-Time PCR Detection System (Biorad,
Hercules, CA) by incubating the reactions at 95 °C for
20 s followed by 40 cycles of 95 °C for 1 s and 60 °C for
20 s. Delta Ct values between human GAPDH and 18S
were calculated and used to generate standard curves
(Additional file 2: Figure S1A). Microsoft Excel was used
to perform nonlinear regression fit and obtain formulas
for human cell number calculations (Additional file 3:
Table S2). Delta Ct values between human GAPDH and
eukaryotic 18S were then obtained for samples from
MSC-injected animals and used to calculate total cell
numbers based on formulas provided in Additional file 3
(Table S2).
Preparation of dead MSC
A total of 3 × 106 MSC in HBSS at 1 × 104 cells/μl were
frozen by immersion into liquid nitrogen followed by
thawing at 37 °C. These steps were repeated three times.
The cells were then placed on ice for injections. The via-
bility of the cells was assayed by trypan blue staining
(Gibco), and more than 99 % of the cells were positive
for uptake of the dye.
Whole tissue, blood, and peritoneal lavage fluid collection
Experimental and control mice were euthanized by cer-
vical dislocation under deep anesthesia. The rib cage
was opened and blood was collected from the right ven-
tricle of the heart and placed in a tube containing clot-
ting activators (Terumo Medical Corporation, Somerset,
NJ) for 20 min and then stored on ice until further pro-
cessing. Serum was separated by centrifugation at
1500 × g for 10 min and stored at –80 °C until further
analysis. To obtain lavage fluid for assays of cytokines,
1 ml of PBS containing Halt Protease inhibitor Cocktail
(Thermo) was injected IP, followed by gentle massaging
and collection of fluid with a sterile pipette. Complete
harvest of the peritoneal cells was obtained by another
injection of PBS (5 ml) followed by lavage harvest. The
cell suspensions from both collections were separately
centrifuged at 500 × g for 10 min at 4 °C. Supernatant
from the first wash was further clarified by centrifugation
at 10,000 × g for 10 min at 4 °C, aliquoted and stored for
further cytokine analysis at –80 °C. The supernatant from
the second wash was discarded and cell pellets were com-
bined and homogenized with Trizol lysis buffer (Qiagen,
Germany), flash frozen in liquid nitrogen, and stored
at –80 °C until further processing. Mouse omentum, jejunal
lymph nodes, mesentery, and spleen were collected and ei-
ther flash-frozen in liquid nitrogen for later RNA isolation,
or placed in sterile HBSS for enzymatic digestion.
In vivo tracking of GFP-MSC
We used male BALB/c mice that were 6–8 weeks of
age and housed on a 12-h light/dark cycle. A total of
2–3 × 106 GFP-MSC in 300 μl HBSS were injected IP
with a 28G needle under brief isoflurane anesthesia.
At 4, 24, 72 and 168 h, the animals were euthanized and
their peritoneal cavities exposed. For the visualization of
GFP-MSC in omentum, the organs were excised from
peritoneal cavities and placed on a plate with a white
background. Lumina IVIS II System (Perkin Elmer,
Waltham, MA) was used to obtain fluorescent images of
the whole peritoneal cavity and individual omenta. Living
Image Software version 4.1 (Perkin Elmer) was used for
GFP fluorescence analysis. To aid in visualization, the
GFP signal was pseudocolored by applying logarithmic
grayscale to the whole peritoneal cavity image or by apply-
ing reverse logarithmic grayscale to the images of the
omenta.
Immunofluorescence of free-floating aggregates
Free-floating GFP+ aggregates were picked with tweezers
from the peritoneal cavity 24 h after the IP injection of
GFP-MSC. The aggregates were washed twice with PBS,
and fixed with 2 % paraformaldehyde (Affymetrix, Santa
Clara, CA) in PBS for 2 h. The fixed aggregates were
washed twice with PBS, centrifuged at 500 × g for 5 min,
and incubated at 4 °C overnight in 1 ml 30 % sucrose
(Sigma) in 0.1 M phosphate buffer (Sigma). After 24 h,
the aggregates were collected in 800 μl of 50 % optimal
cutting temperature compound (OCT; Sakura Finetek,
Torrance, CA) and transferred into a histology mold.
The mold was frozen in isopentane (Sigma), chilled by
liquid nitrogen and stored at –80 °C. Cryosections
(6 μm) were prepared with a Microm HM560 cryostat
and incubated for 20 min at room temperature before
storing at –80 °C. For the immunofluorescent staining,
sections were equilibrated to room temperature, fixed
again for 10 min in 2 % paraformaldehyde and washed
twice in Tris-Buffered Saline with Tween (TBST; Cell
Signaling, Beverly, MA). Nonspecific antibody binding
was blocked by incubating samples for 45 min in TBST
supplemented with 5 % bovine serum albumin (BSA;
Thermo Fisher Scientific, Whaltman, MA) and 5 % nor-
mal serum (Thermo). Following two washes in TBST,
samples were incubated for 24 h at +4 °C with primary
antibodies to mouse CD11b (catalog #550282; BD
Pharmingen, Frankling Lakes, NJ) at 1:100 dilution in
blocking solution, or isotype control antibody. Sec-
tions were washed three times in TBST, incubated for
1 h at room temperature with anti-rat Alexa-594 con-
jugated secondary antibodies (Life Technologies,
Grand island, NY) at 2 μg/ml in blocking solution,
then counterstained with 0.5 μg/ml of 4,6-diamidino-
2-phenylindole (DAPI; Sigma) in PBS for 10 min. The
sections were washed three times in TBST and mounted
in Prolong Gold antifade reagent (Life Technologies)
overnight.
Bazhanov et al. Stem Cell Research & Therapy  (2016) 7:27 Page 4 of 14
Whole mount immunofluorescence of aggregates in the
mesentery and omentum
Whole omenta or portions of mesentery with visible
GFP+ clusters were removed from the peritoneal cavity
24 h after GFP-MSC injection, washed twice with PBS,
and fixed with 2 % paraformaldehyde in PBS for 2 h.
Fixed tissues were washed twice with PBS and blocked
by incubation in TBST with 5 % BSA and 5 % nor-
mal serum for 45 min at room temperature. Samples
were washed twice with TBST, and incubated for
24 h at +4 °C with primary antibody to mouse
CD45R (catalog #550286; BD Pharmingen) or isotype
control antibody at 1:100 dilution in blocking solution.
Tissues were then washed three times in TBST, incubated
for 1 h at room temperature with anti-rat Alexa-594
conjugated secondary antibodies (Life Technologies)
at 2 μg/ml in blocking solution, then counterstained
with 0.5 μg/ml DAPI in PBS for 10 min. The tissues
were placed on a glass slide and covered with a
coverslip.
Immunofluorescent image acquisition and manipulation
Low magnification (1–2×) bright-field and GFP images
were captured with Nikon Digital Sight DS-2Mv camera
attached to a SMZ800 dissecting microscope (Nikon,
Japan). Illumatool Bright Light Systems LT 9900
(Lightools Research) with GFP filter set (470 nm excita-
tion and 515 nm emission) was placed under the object-
ive of the microscope to visualize GFP fluorescence.
High magnification images were obtained using Nikon
Eclipse 80i upright microscope and processed using NiS
Elements AR3.0 software (Nikon, Japan). All image
manipulations (merging, brightness and contrast ad-
justment) were performed using ImageJ Version 1.49a
(NIH, US).
Real-time PCR for mouse cytokines
Mouse omenta, jejunal lymph nodes, mesentery, spleen
and cell pellet that included MSC aggregates from peri-
toneal lavage were obtained as described above and
flash-frozen in liquid nitrogen. The tissues were homog-
enized in Trizol lysis buffer (Qiagen, Germany) and total
RNA was isolated using RNeasy Lipid Tissue Mini Kit
(Qiagen) with DNA digestion step using DNAse
(Qiagen). Isolated RNA was quantified using Nanodrop
specrophotometer (Thermo Fisher Scientific) and 0.3–
2 μg was converted to cDNA with High-Capacity cDNA
RT Kit (Applied Biosystems, Foster City, CA). Real-
time PCR for mouse Il10, Il13, Ifng and Ptgs2 was
performed using Taqman Gene Expression Assays
(Applied Biosystems) and Taqman Fast Master Mix
(Applied Biosystems) in triplicate using 20 ng cDNA
in 20 μl reaction. Real-time PCR reaction was per-
formed with CFX96 Real-Time PCR Detection System
(Biorad, Hercules, CA) by incubating the reactions at
95 °C for 20 s followed by 40 cycles of 95 °C for 1 s
and 60 °C for 20 s. Calculated delta-Ct values be-
tween gene of interest and Gapdh were used to ob-
tain relative expression values (2–ΔCt).
Assays of cells in the omentum
Omenta were excised from the animals and placed
in HBSS with calcium and magnesium containing
0.8 mg/ml dispase/collagenase, 0.2 mg/ml collagenase P
and 0.1 mg/ml DNAse I (Roche Molecular Diagnostics,
USA, Pleasanton, CA). The omenta were minced and in-
cubated at 37 °C for 60 min with gentle pipetting every
15 min. The digest was then diluted 10 times with calcium
and magnesium-free HBSS, strained via a 70-μm nylon
mesh and centrifuged at 500 × g for 5 min at room
temperature. The supernatant was discarded and the cell
pellet was resuspended in calcium- and magnesium-free
HBSS, centrifuged again, and resuspended in HBSS
containing 2 % BSA, followed by cell counting with
hemocytometers. The cells were then incubated for
10 min at 4 °C with anti-CD16/32 antibody at a con-
centration 0.5 μg per 1 × 106 cells in 100 μl of PBS
containing 1 % BSA (eBioscience) to block nonspecific
binding to Fc-receptors. After one wash with PBS
supplemented with 1 % BSA, the cells were incubated
for 20 min at room temperature with fluorescently
conjugated antibody against mouse F4/80
(eBioscience), Ly6G, CD19, CD3, CD8, and CD45R (BD
Pharmingen). The antibodies were used at a concentration
of 1 μg per 1 × 106 cells in 100 μl PBS supplemented
with 1 % BSA. Isotype-matching antibodies at similar
concentrations obtained from the same manufacturers
and single-color labeling were used as controls for
the specificity of labeling. After two washes in PBS,
the cells were resuspended in PBS supplemented with
1 % BSA and analyzed by flow cytometer (Model
FC500; Beckman Coulter, USA, Brea, CA) to deter-
mine macrophage (F4/80-positive), neutrophil (Ly-6G-
positive), T-cell (CD3- or CD8-positive) and B-cell
(CD19- or CD45R-positive) populations.
Assays for mouse secreted cytokines
Mouse IL-6, IL-10, IL-12p70, interferon (IFN)γ, mono-
cyte chemotactic protein-1 (MCP1), chemokine (C-X-C
motif ) ligand 1 (CXCL1), transforming growth factor
(TGF)β1, tumor necrosis factor (TNF)-α and prostaglan-
din (PG)E2, in peritoneal lavage and/or serum, were
assayed with commercial enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems Inc, Minneapolis,
MN). Mouse IL-13 was assayed with commercial ELISA
kit from Life Technologies. For all assays, optical density
was determined on a plate reader (FLUOstar Omega;
BMG Labtech, Germany) at an absorbency of 450 nm
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with wavelength correction at 540 nm for the optical im-
perfections on the plate.
Lipopolysaccharide injury model in mice
Male 6-week-old BALB/c mice were injected IP with
3 × 106 MSC or dead MSC, prepared as described above.
Sterile HBSS injections were used as controls. At 3 days
after the MSC delivery, the animals were injected with
lipopolysaccharide (LPS; Sigma) at 0.1 mg/kg body weight
via the tail vein. Three hours after the administration of
LPS, tissues were harvested and lavage fluid collected.
Data analysis and presentation
When comparing two groups, the unpaired t-test was
used, whereas one-way analysis of variance (ANOVA)
with Bonferroni’s post-hoc analysis was used in multiple
comparisons. One-way ANOVA with Dunett’s post-hoc
analysis was used to compare groups to a control. Null
hypotheses were rejected at P values less than 0.05. All
statistical analyses and chart preparations were per-
formed with GraphPad Prism 6 software (GraphPad
Software, Inc., USA, La Jolla, CA). Curve fitting was per-
formed using Microsoft Excel Software. Images and
charts were combined and annotated using Inkscape
Software.
Results
IP administration of different human MSC preparations
and fibroblasts
Different preparations of MSC from human bone mar-
row vary in their properties and biological activities, a
feature loosely referred to as donor variation [35, 36].
Therefore we administered three different preparations
of MSC IP in mice and compared their effects on the
levels of mouse cytokines in peritoneal lavage fluid. All
three increased the levels of IL-10, IL-13 and PGE2 but
not IL-4 or IL-12p70 (Fig. 1a). Because MSC designated
as Donor 7075 had the most consistent effects, we
employed the Donor 7075 in further experiments. The
IP administration of Donor 7075 MSC demonstrated a
progressive increase in the levels of IL-10, IL-13 and
PGE2 with 0.3, 1 and 3 × 10
6 (Fig. 1b). In addition, an in-
crease in systemic IL-13 and IL-10 was observed after IP
administration of MSC donor 7075 (Additional file 4:
Figure S2). Therefore we employed administration of
3 × 106 MSC in further experiments. Similar increases in
the three responding cytokines (IL-10, IL-13 and PGE2)
were observed after IP administration of human skin fi-
broblasts (Fig. 1c). Therefore the effects were not spe-
cific to administration of MSC.
Fate of human MSC in the peritoneal cavity
To study the fate of MSC injected into the peritoneal
cavity, GFP-labeled human MSC were used. To detect
single GFP-labeled cells in the peritoneal cavity, 5 ml of
PBS was injected IP and the harvested lavage fluid was
examined in a hemocytometer (Fig. 2a and b). One
minute after injection, 75 % of the injected GFP-
labeled cells were accounted for (Fig. 2). Surprisingly,
the number fell to less than 10 % after 20 min. At
the same time, there was a marked decrease in the
total number of mouse cells in the lavage fluid, ap-
parently because macrophages and some lymphocytes
in the peritoneal cavity had aggregated with the MSC
[37]. The number of murine single cells increased by
4 h and it continued to increase for at least 72 h
(Additional file 2: Figure S1B).
Aggregation of the injected MSC was demonstrated by
assays of the pellet obtained by low-speed centrifugation
(500 × g for 10 min) of the peritoneal lavage. Four hours
after injection of the MSC, assays by real-time PCR for
human GAPDH mRNA demonstrated that about 50 %
of the injected human cells were recovered in the pellet
(Fig. 2c; Additional file 2: Figure S1A; Additional file 3:
Table S2; and Additional file 5: Table S3). However, at
1 day, only about 1 % of the injected cells were recov-
ered in the pellet of the peritoneal lavage (Fig. 2c), ap-
parently because the aggregates had attached to the
mesentery, omentum and other surfaces of the periton-
eal cavity. Of special interest was that less than 1500, or
0.05 %, of the injected 3 × 106 cells were found in the
spleen and jejunal lymph nodes at any of the time points
examined (insert in Fig. 2c).
To examine the fate of the injected cells further, we
injected GFP-MSC IP and opened the peritoneal cavity
to follow the distribution of the cells by in vivo fluores-
cent imaging (Fig. 3). As expected from the assays of the
lavage pellet (Fig. 2c), numerous aggregates of GFP-
positive cells were found as free-floating in the periton-
eal cavity at 4 h (Fig. 3a and b). At 1 day, the GFP-
positive aggregates appeared to have increased in size
and become attached to multiple surfaces within the
peritoneal cavity. Many were easily detached by flushing
with PBS or lifting with tweezers. However, the aggre-
gates that attached to the omentum and to sites within
the mesentery were firmly adherent and appeared to be
embedded within the tissues. At 3 days, there was a de-
crease in GFP-labeled aggregates and at 7 days they were
no longer detected.
To examine the composition of the aggregates, GFP-
MSC were injected IP, and GFP-positive aggregates in
the peritoneal lavage, mesenteric sites, and the omentum
were isolated after 24 h and examined (Fig. 4a). Im-
munofluorescent images of sections of aggregates from
the peritoneal lavage demonstrated that they were rich
in cells positive for CD11b + (Fig. 4b), a marker for mac-
rophages. Immunohistochemistry of whole mounts of
aggregates from mesenteric sites and the omentum
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demonstrated that they were rich in B220+ cells (Fig. 4c),
a marker expressed in various immune cells including
B1 lymphocytes that are the predominant lymphocytes
of the peritoneal cavity and the omentum, macrophages,
T cells and dendritic cells. The micrographs and a z-stack
video of an aggregate from the omentum demonstrated
that the GFP-MSC were at the center of the aggregates
without any specific orientation (Online Additional file 6:
Video S1).
The MSC aggregates in the omentum recruit
macrophages and lymphocytes
Since the omentum was a major site for the firm attach-
ment of the aggregates, the organ was excised and
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examined. Fluorescence assays indicated that the con-
tent of GFP-MSC increased sharply by 4 h, decreased
by 3 days and were not detected by 7 days (Fig. 5a).
As the MSC decreased, there was a marked increase
in the weight of the omentum (Fig. 5b), the total cell
content (Fig. 5c), and macrophage content (Fig. 5d),
observations suggesting recruitment of macrophages
and lymphocytes into the omentum that continued
after most of the MSC had disappeared (Additional
file 2: Figure S1B).
IP injection of MSC triggers increased expression of
murine cytokines and preconditions the immune system
The IP infusion of MSC stimulated increased secretion
of a series of mouse cytokines into the peritoneal lavage in
a time-dependent manner (Additional file 7: Figure S3).
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To define the source of the cytokines detected in the lav-
age after injection of MSC, we used real-time PCR assays
of omentum, mesentery, cells from peritoneal lavage, and
jejunal lymph nodes (Additional file 7: Figure S3D). The
results suggested that the omentum was the major source
of the increases in expression of mouse Il10, Ifng and Il13
but both the omentum and the cells in the peritoneal
lavage made major contributions to the increase in Cox2
(cyclooxygenase; prostaglandin-endoperoxide synthase).
Human MSCs showed distinct change in their gene ex-
pression profiles after administration inside the peritoneal
cavity. Real-time PCR assays showed upregulation of
human TGFβ1, COX2 and TSG6 in injected cells in the
peritoneal cavity in comparison to unstimulated in vitro
cultures of MSCs.
The persistence of changes in the peritoneum sug-
gested that the IP infusion of MSC had pre-conditioned
the immune system of the mouse. Therefore, we tested
the effects of challenging the mice with the bacterial
extract LPS. Mice received an IP injection of MSC
followed by IV infusion of LPS 3 days later. Three hours
after the LPS injections, the mice were sacrificed and the
chest
omentum
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cavity
aggregates
aggregates
mesentery
diaphragm
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µW/cm2
1081091010
Control 4 hours 1 day 3 days 7 days
150 mm
150 mm
A
B
Fig. 3 In vivo fluorescent imaging of GFP-MSC in the peritoneal cavity. a Depiction of GFP-MSC distribution in the peritoneal cavity of BALB/c
mice 24 h after IP administration. Yellow dashed lines outline GFP-positive areas (bright white) corresponding to the omentum, aggregates and
portions of mesentery. b Representative images of the peritoneum of BALB/c mice injected IP with GFP-MSC and followed by in vivo fluorescent
imaging. Bright white areas correspond to the areas of GFP-positive cells. Logarithmic grayscale was applied to panels (a) and (b) to help in
visualization of the GFP signal
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lavage fluid was collected for cytokine measurements
(Additional file 8: Figure S4). Among the early respond-
ing cytokines, the preconditioning enhanced the expres-
sion of IL-12p70, MCP1, and CXCL1 (Additional file 8:
Figure S4A). Among the intermediate responding
cytokines, preconditioning enhanced the levels of IL-10
and greatly enhanced the levels of IFNγ and TNFα
(Additional file 8: Figure S4B). MSC preconditioning
had no effect on the levels of the late responding cyto-
kines PGE2 and IL-13 (Additional file 8: Figure S4C). Of
special importance was the observation that MSC
killed by repeated cycles of freezing and thawing had
little effect in preconditioning the immune system, an
observation that suggested an active rather than pas-
sive role of the IP-delivered MSC.
Discussion
The results demonstrated that, after human MSC were
injected into peritoneum of immune-competent mice,
they quickly formed aggregates with the resident macro-
phages and the B220+ cells of the peritoneal cavity. The
aggregation was so rapid that less than 10 % of the MSC
were recovered as single cells in the peritoneal lavage
after 20 min. At 4 h, about half of the injected MSC
were recovered in the peritoneal lavage fluid as aggregates
that were readily isolated by low-speed centrifugation. At
Fig. 4 Colocalization of human GFP-MSC with immune cells in the peritoneal cavity. Representative immunofluorescent images of human GFP-MSC in
free-floating aggregates, and aggregates attached to the mesentery and omentum 24 h after their IP administration. a In vivo low-magnification (1.5×)
images. b GFP-positive aggregates as shown in (a) were obtained from the peritoneal cavity, cryosectioned and stained with CD11b antibody
(magnification 20×). c GFP-positive aggregates attached to the mesentery and omentum were isolated with tweezers, fixed, labeled with B220
antibody, and examined as whole mounts (magnification 20×). Representative images from three mice. DAPI 4′,6-Diamidino-2-phenylindole; GFP
green fluorescent protein, MSC mesenchymal stem cells
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1 day, only a few of the aggregates containing MSC were
found in the peritoneal lavage. Instead they were found as
aggregates attached to multiple sites in the peritoneal cav-
ity. Most of the aggregates were loosely attached but those
attached to the omentum and sites within the mesentery
were embedded within the tissues. The survival and
viability of the human cells was assessed by real-time
RT-PCR for mRNA specific for human GAPDH and
measuring levels of GFP fluorescence emitted by
GFP-MSC. Both signals that reflect live cells indicated
that the cells survived transiently and most disap-
peared after about 3 days.
Surprisingly, less than 1 in 3000 (0.003 %) of the
injected cells were recovered in jejunal lymph nodes or
the spleen. The results present a contrast to previous ob-
servations with IP injections of splenocytes in which
most of the cells passed into the lymphatic system and
accumulate in lymph nodes [31]. The results therefore
indicated that, apparently because of the rapid aggrega-
tion, the MSC had limited direct access to lymphatics.
However, it is necessary to mention that the human
MSC could have also lacked the specific human signals
required for migration to lymph nodes or the spleen in
the mouse environment.
One interesting observation was that although the
number of MSC in the omentum rapidly decreased after
3 days they initiated a cascade whereby large numbers of
mouse cells were recruited to the omentum and the
organ doubled in weight. The observations are probably
explained by the peaks of the proinflammatory mouse
cytokines IL-6 and IL-12p70 at 4 h and IFNγ and
TNFα at 72 h that probably attracted and activated
macrophages.
The rapid aggregation of MSC with macrophages and
B220+ cells explains some of the therapeutic effects pre-
viously observed with IP administration of MSC in ani-
mal models. As reported previously [30], the MSC in the
aggregates formed in the peritoneum within 4 h were ac-
tivated to express high levels of potentially therapeutic
human genes such as the genes for the natural anti-
inflammatory protein TSG-6, for COX2 that is a critical
enzyme in the synthetic pathway for PGE2, and for STC-
1 that can reduce reactive oxygen species. The activation
was more rapid than seen with human MSC cultured as
hanging drops under conditions in which the cells con-
dense into spheres, and it is probably accelerated by the
presence of the macrophages and B220+ cells in the ag-
gregates. The rapid activation of human MSC injected
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Fig. 5 IP injected MSC localized to the omentum and recruit immune cells. a Ex vivo fluorescent images of the omenta excised from
GFP-MSC-injected BALB/c mice. To help in visualization of the GFP signal in the transparent omentum, reversed logarithmic grayscale was
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IP into immunocompetent mice probably explains the
effectiveness of this route of administration of human
MSC in two models of sterile inflammation: ethanol in-
jury to the cornea [12] and zymosan-induced peritonitis
[13]. In the cornea model, the window for effective ther-
apy is less than 6 h [38] and, in the peritonitis model,
the beneficial effects were seen within 4 h [13]. In both
models, the therapeutic responses were linked to expres-
sion of TSG-6, since MSC with a silencing-RNA knock-
down of the TSG-6 gene were ineffective and most of
the effects of MSC were reproduced by administration
of recombinant TSG-6. In the present study we also
show the upregulation of TSG-6 in injected MSCs. Simi-
lar rapid activations of IP MSC may also explain some of
the therapeutic effects observed in other models [8–11].
The MSC used in the reported experiments were either
isogeneic or allogeneic but could have invoked the rapid
reactions of the peritoneal macrophages and B1 lympho-
cytes because the MSC acted as foreign bodies in the
peritoneum, or because they had acquired foreign anti-
gens during their isolation and expansion in culture. As
shown previously [39], MSC rapidly internalize large
amounts of fetal bovine proteins from the medium used
to culture the cells and the internalized proteins stimu-
late immune responses after IV infusions of the cells
into mice. The isogeneic mouse MSC used by Yousefi et
al. [8], Scruggs et al. [9], and Cheng et al. [10] were all
isolated and expanded in medium containing high con-
centrations of FBS. In the Wistar rat model for induced
colitis study, Castelo-Branco et al. [11] used bone mar-
row- and adipose-derived MSC that were isolated and
expanded in 15 % or 20 % fetal calf serum. Therefore, ei-
ther the cells themselves, or the foreign proteins they
carried, could have prompted rapid aggregation with
peritoneal macrophages and B220+ cells and the sub-
sequent activation of therapeutic genes in the MSC.
Sorting out these possibilities is technically challen-
ging because of the tendency of mouse MSC to
undergo spontaneous transformation during expansion
in culture [40, 41], and the extensive manipulations
of MSC in culture required to remove internalized
fetal calf proteins [39].
One of the limitations of the present study is that hu-
man MSC were employed in immunocompetent mice.
Therefore, some of the effects can be ascribed to inflam-
matory and immune reactions to xenogeneic cells. How-
ever, comparable experiments with mouse MSC are
limited by the inability of the cells to be expanded sig-
nificantly without undergoing spontaneous transform-
ation [40, 41]. Another limitation is that the data did not
establish whether the MSC were more effective in pre-
conditioning the immune system than cells such as fi-
broblasts. However, the data demonstrated that three
preparations of human MSC isolated and expanded with
the same protocols varied in their efficacy. Therefore, it
will probably be necessary to compare large numbers of
different preparations of MSC and large numbers of
control cells to establish which are the most effective.
The results did establish that live MSC were far more ef-
fective than dead MSC in preconditioning the mice in
their response to LPS. Therefore the results were not ex-
plained by inflammatory or immune reactions to human
cellular proteins or cell debris.
Conclusions
In conclusion, we demonstrated that IP injected human
MSC quickly aggregate and the aggregates attach to the
mesentery, omentum and other sites in the peritoneal
cavity. In contrast, only small amounts of the cells mi-
grate to the spleen and jejunal lymph nodes. Aggregation
and attachment to tissues was accompanied by the re-
cruitment of immune cells and sequential changes in the
production of mouse cytokines. The formation of the
aggregates probably limits access of the cells to the sys-
temic circulation.
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Additional file 1: Table S1. Characteristics of the MSC donor samples
used in the current study. (PDF 56 kb)
Additional file 2: Figure S1. Detection of MSC in mouse tissues and
peritoneal lavage by real-time PCR. (A) Standard curves of known amounts
of human cells added to mouse tissues plotted versus corresponding delta
Ct values (Ct human GAPDH – Ct values eukaryotic 18S) obtained by real-
time PCR in the same tissues. Points represent average values for delta-Ct,
lines represent logarithmic model fit. (B) Peritoneal lavage from human
MSC-injected BALB/c was collected and total number of recovered cells was
enumerated with hemocytometer. Values are mean ± SEM, n = 4–5. OM
omentum, MT mesentery, PLP cell pellet from peritoneal lavage, JLN jejunal
lymph nodes, SP spleen. (PDF 58 kb)
Additional file 3: Table S2. Goodness of logarithmic fit of standard
curves. (PDF 44 kb)
Additional file 4: Figure S2. Effects of IP injected MSC to cytokine
levels in the mouse serum. Mouse IL10 and IL13 levels in the serum were
assayed 72 h after IP injection of MSC. (PDF 18 kb)
Additional file 5: Table S3. Biological replicates of Ct values for
eukaryotic 18S and human GAPDH assayed by real-time PCR in mouse
tissues after MSC administration. (PDF 77 kb)
Additional file 6: Video S1. Z-stack of GFP-MSC aggregate in omentum.
Omentum from GFP-MSC injected animal was isolated after 24 h post
administration, fixed and labeled for B220. Z-stacks with step of 5 μm
was obtained and converted into AVI video file using ImageJ software.
Human GFP-MSC are seen in the center of the aggregate (green), while
B220-positive cells lymphocytes have no specific localization and are
seen in the center and also at the periphery of the aggregate. Magnification
20 ×. (AVI 5314 kb)
Additional file 7: Figure S3. Production of mouse cytokines in the
peritoneal cavity after MSC administration. Mouse cytokines were assayed
in peritoneal lavage of MSC-injected BALB/c mice. Based on the timing of
the cytokine production, they were categorized into (A) early- (peak
production within 4 h), (B) intermediate- (peak production on day 3),
or (C) late-responding cytokines (peak production beyond day 3). Data
are representative of two independent experiments. Values are arithmetic
means ± SEM, n = 4–6. (D) Relative gene expression of selected mouse
cytokines in omentum (OM), mesentery (MT), peritoneal lavage pellet (PLP)
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and jejunal lymph nodes (JLN). Values are average gene expression values
normalized to mouse Gapdh using 2–ΔCt method ± SEM, n = 4 to 5.
*P < 0.05; **P < 0.01; ***P < 0.001 compared to baseline expression
levels. (E) Relative gene expression of human cytokines in omentum,
mesentery, peritoneal lavage pellet and jejunal lymph nodes. Values
are fold change of gene expression in vivo over corresponding gene
expression in unstimulated in vitro cultures of MSCs prior to the injection
into mice represented on the graph by dotted line. The expression values
were obtained using 2–ΔΔCt method with human GAPDH as housekeeping
control. (PDF 105 kb)
Additional file 8: Figure S4. Preconditioning of the mouse immune
system by IP injected MSC. Live or dead MSC were injected IP into BALB/c
mice 3 days prior to systemic administration of LPS. Identical experiments
without LPS administration were performed in naïve mice. Mouse cytokines
in the peritoneal lavage were measured at 3 days after MSC administration
and 3 h after LPS administration. Based on the timing of the cytokine
production, they were categorized into (A) early- (peak production
within 4 h), (B) intermediate- (peak production on day 3), or (C) late-
responding cytokines (peak production beyond day 3). Values represent
mean ± SEM, n = 4–7. *P < 0.05; **P < 0.01; ***P < 0.001 compared to
vehicle controls in each experimental setting. The Y-axis is logarithmically
transformed. (PDF 62 kb)
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